Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | KDM4B | O94953 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651553 | 0.85 | RAB9A (0.49) | ECE1RAB9AHTTKDM4EPOLB | |
| SCHEMBL3061177 | 0.85 | RAB9A (0.52) | ECE1RAB9AHTTKDM4EPOLB | |
| SCHEMBL27713031 | 0.81 | NPC1 (0.55) | RAB9AKDM4EKDM4AKDM4BKDM5C | |
| SCHEMBL12507345 | 0.80 | ECE1 (0.54) | ECE1RAB9AKDM4EPOLBNPC1 | |
| SCHEMBL3141920 | 0.77 | RAB9A (0.43) | ECE1RAB9AHTTKDM4EPOLB | |
| SCHEMBL31039827 | 0.74 | PTPN1 (0.55) | ECE1RAB9AHTTKDM4ENPC1 | |
| SCHEMBL22619827 | 0.74 | PTPN1 (0.55) | ECE1RAB9AHTTKDM4ENPC1 | |
| SCHEMBL457097 | 0.74 | — | — | |
| SCHEMBL4405261 | 0.73 | ALDH1A1 (0.49) | RAB9AHTTKDM4ENPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20606395 | 0.72 | ECE1 (0.54) | ECE1RAB9AHTTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| EP-2699560-B1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-9233957-B2 | 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-12 | — | — | US | disclosed |
| EP-2601208-B1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2015-02-11 | — | — | EP | disclosed |
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-08 | — | — | US | disclosed |
| EP-2699560-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2014-02-26 | — | — | EP | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| EP-2601208-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | Graffinity Pharmaceuticals GmbH (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2012169863-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012017021-A2 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2012-02-09 | — | — | WO | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | ECE1 1636/4885RAB9A 1446/4885HTT 4069/4885 |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | ECE1 3759/4885RAB9A 2580/4885HTT 1054/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | ECE1 1490/4885RAB9A 967/4885HTT 558/4885 |
| US-20170152288-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCGR3B | ECE1 3140/4885RAB9A 3306/4885HTT 3846/4885 |
| US-20140128427-A1 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | HSD3B1, HSD11B1, HSD3B2 | ECE1 642/4885RAB9A 759/4885HTT 1992/4885 |
| US-20130131321-A1 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY | FCGR1A, FCGR2A, FCER2 | ECE1 3958/4885RAB9A 3980/4885HTT 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.